Pharmafile Logo

global access

Gamification for patient care, medical education, and virtual engagement

“Gamification”–adding game-like elements into non-game or real-world settings–has become a popular concept in the pharmaceutical, healthcare, and event industries. However, it is proving more than a mere buzzword. With diverse...

Impetus Digital

- PMLiVE

FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma

The FDA submission for Brukinsa in MZL includes results from the phase 2 MAGNOLIA trial

- PMLiVE

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

SGLT2 inhibitor failed to significantly reduce the number of patients who experienced organ failure or died compared to placebo

- PMLiVE

Sandoz reveals antibiotic manufacturing expansion plans in Europe

Builds on company's previous commitments to drive the long-term future of integrated antibiotics manufacturing in Europe

- PMLiVE

eureKARE to use $60m financing to bolster next-generation European biotech companies

New company is focused on financing biotech companies and new ventures in Europe working on the microbiome and synthetic biology

- PMLiVE

Sarepta Therapeutics’ DMD gene therapy shows early success

Most patients with Duchenne muscular dystrophy require full-time use of a wheelchair by their early teens

Understanding the role of provider collaboratives

Oli Hudson, Content Director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care.

Wilmington Healthcare

- PMLiVE

GSK and Medicago’s COVID-19 vaccine shows promising antibody responses in phase 2

Neutralising antibody responses in vaccinated participants were about ten times higher than those seen in a panel of sera from recovering COVID-19 patients

- PMLiVE

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

Amgen will retain market exclusivity on blockbuster arthritis drug until 2029

- PMLiVE

Detailed results for Regeneron’s antibody cocktail continue to show benefit in high-risk COVID-19 outpatients

Treatment shortened symptom duration and reduced viral load in non-hospitalised patients with COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links